U.S. stock index futures pointed to a solidly lower open, as investors got ready to wade through another downpour of earnings.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
A new drug being tested slows Alzheimer's by removing plaque buildup in the brain. It's hope for millions suffering from the disease.
U.S. stocks steadied Wednesday, closing narrowly mixed after the Fed minutes affirmed previous expectations for a possible December rate hike.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
CNBC took a deep look at stocks in one urban area that have produced big stock returns in a wide diversity of industries.
The "Fast Money" traders debated whether it's time to pile into the biotech sector after the sector gained 3 percent on Monday.
The "Fast Money" traders give you 5 trades in biotech.
Aside from the financial crisis, health care hasn't lagged the broader market this badly since Bill Clinton was president.
The "Fast Money Halftime Report" traders and Stephanie Link, TIAA Global Asset Management, take their positions on four stocks making news today, including Goodyear Tire, Mondelez and more.
With biotechs in the political crosshairs, is now the time to look at the space? With Michael Yee, RBC Capital biotech analyst.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Wharton professor Jeremy Siegel predicted that the market would rally, here's what he sees next.
Endo International shares surged after it posted second-quarter earnings that exceeded analysts expectations and appointed new management.
Jim Cramer outlined the stocks and events he will be watching next week, and has his eye on one cohort.
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
CNBC's Landon Dowdy takes a look at the best performing sectors and stocks in the S&P 500 this summer so far.
Jim Cramer identified four groups to embrace and avoid in the market, including one with a powerful growth story.
The $75 billion Biogen may be vulnerable to a takeover, but it makes a risky target at a likely value approaching $90 billion.